Clinical Trials Using Niraparib Tosylate Monohydrate
Clinical trials are research studies that involve people. The clinical trials on this list are studying Niraparib Tosylate Monohydrate. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients With Platinum Resistant Ovarian Cancer
This is an open-label, single-arm Phase 2 study to evaluate the efficacy and safety of combination of niraparib and TSR-042 in patients with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal cancer without known BRCA mutation who have platinum-resistant disease and who have also been previously treated with bevacizumab.
Location: 12 locations
Niraparib and Tumor-Treating Fields for the Treatment of Recurrent Glioblastoma
This phase II trial evaluates the safety and effectiveness of an investigational drug called niraparib in combination with tumor-treating fields for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrence). Niraparib makes it harder for tumor cells to repair their DNA (the instructions inside the tumor cell that make it grow), which can lead to the death of tumor cells. Electric forces called tumor-treating fields may disrupt the growth of tumor cells. These tumor-treating fields are given to patients using a device called Optune. Giving niraparib and tumor-treating fields together may work better than the individual use of each intervention for the treatment of patients with recurrent glioblastoma.
Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania